Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04260217
Title APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ascentage Pharma Group Inc.
Indications

Waldenstroem's macroglobulinemia

Therapies

APG-2575

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.